Artelo Biosciences, Inc. Common Stock
ARTL XNASAbout Artelo Biosciences, Inc. Common Stock
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0 | $-3,120,000 | N/A |
| Q1 2025 | $0 | $-2,372,000 | N/A |
| FY 2024 | $0 | $-9,826,000 | N/A |
| Q3 2024 | $0 | $-1,132,000 | N/A |
TickerDaily Coverage
Get ARTL Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Artelo Biosciences, Inc. Common Stock.